3 December 2013
Dechra® Pharmaceuticals PLC
("Dechra" or "the Company")
Director / PDMR shareholding
Dechra Pharmaceuticals PLC has been notified that Ian Page, Executive Director, has today exercised SAYE options over 5,316 ordinary shares of 1p each ("Ordinary Shares") at an exercise price of £3.1502 per share.
Following this acquisition, Ian Page's beneficial interest in the Company is 865,067 shares (0.991% of the current issued share capital).
For further information, please contact:
Zoe Goulding, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals business. Its expertise is in the development, manufacturing and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.